Can you take Mounjaro with SGLT2 inhibitors?

Jump to: Understanding SGLT2 inhibitors | How Mounjaro and SGLT2 inhibitors work together | Safety considerations | NHS guidance | Practical advice | What to expect | Frequently asked questions | Take home message

You can take Mounjaro (tirzepatide) alongside SGLT2 inhibitors, such as empagliflozin, dapagliflozin, or canagliflozin.

Clinical trials, including the SURPASS program, have evaluated this combination and found it both effective and generally well-tolerated.

Many patients worry about the side effects overlapping, particularly dehydration, but research suggests the benefits often outweigh these manageable risks when proper monitoring is in place.

Both medications work through different mechanisms, creating complementary effects for blood sugar control and weight loss.

Clinical trials have shown that patients may experience improved HbA1c reductions and enhanced weight loss when using both treatments together compared to either medication alone.

It’s essential to prioritise hydration, closely monitor for specific side effects, and work closely with your healthcare team to determine the most suitable dosing schedule.

Current clinical guidelines support considering this combination, particularly for patients who haven’t achieved target blood sugar levels on single medications alone.

Understanding SGLT2 inhibitors

SGLT2 inhibitors work differently from Mounjaro. While Mounjaro mimics hormones that affect hunger and insulin function (to manage blood sugar), SGLT2 inhibitors work directly in our kidneys.

SGLT2 inhibitors work by helping our body excrete excess sugar (glucose) out of our urine.

Normally, our kidneys filter sugar but then reabsorb most of it back into our bodies. SGLT2 inhibitors block this reabsorption, causing excess sugar to be excreted in our urine.

The three most commonly prescribed SGLT2 inhibitors in the UK are:

1. Empagliflozin (Jardiance) – Often prescribed for patients with heart failure or kidney disease
2. Dapagliflozin (Forxiga) – May be prescribed for patients with heart failure, even without diabetes
3. Canagliflozin (Invokana) – Another option in this medication class

Beyond lowering blood sugar, research shows SGLT2 inhibitors offer several other potential benefits:

• Modest weight loss
• Reduced risk of heart failure hospitalisation
• Kidney protection, particularly for those with early kidney disease
• Lower blood pressure

These medications are taken once daily as tablets, unlike Mounjaro, which is a weekly injection.

Most patients take SGLT2 inhibitors in the morning, though timing isn’t as crucial as with some other medications.

How Mounjaro and SGLT2 inhibitors work together

Combining Mounjaro and SGLT2 inhibitors may offer complementary benefits to manage blood sugar and support weight loss.

Mounjaro primarily works by:

• Mimicking two hormones (GLP-1 and GIP) that help regulate blood sugar
• Slowing stomach emptying to reduce post-meal blood sugar spikes
• Reducing hunger by communicating with our brain
• Improving insulin sensitivity

Meanwhile, SGLT2 inhibitors:

• Remove excess sugar through urine
• Don’t depend on insulin to work
• May lower blood pressure
• Reduce overall fluid volume in the body

The SURPASS clinical trials showed that patients already taking SGLT2 inhibitors who added Mounjaro achieved significant improvements. Specifically, research demonstrated:

• HbA1c reductions of 1.8–2.4% when adding Mounjaro to existing treatments, including SGLT2 inhibitors
• Greater improvements in multiple health measurements compared to single-drug approaches

This complementary action makes sense because they target different aspects of diabetes.

Mounjaro addresses insulin resistance and appetite, while SGLT2 inhibitors handle excess sugar elimination regardless of insulin status.

This combination may be particularly relevant for patients with:

• Persistent elevated HbA1c despite monotherapy
• Existing cardiovascular disease or high-risk factors
• Obesity requiring significant weight loss
• Early kidney disease

Safety considerations

While this combination offers significant benefits, there are important safety considerations to understand.

The most common concerns involve overlapping side effects:

Dehydration risk

Both medications can increase urination and fluid loss. This combination requires extra attention to hydration, particularly during:

• Hot weather
• Exercise
• Illness with fever or gastrointestinal symptoms
• The first few weeks after starting either medication

Genital infections

SGLT2 inhibitors increase sugar in the urine, which can raise the risk of genital thrush or yeast infections. Good hygiene practices are essential, particularly for women.

Hypoglycaemia concerns

When used together without insulin or sulfonylureas, the risk of dangerously low blood sugar is quite low. However, if you take insulin or sulfonylureas alongside this combination, your doctor will likely need to reduce those doses.

Ketoacidosis awareness

SGLT2 inhibitors slightly increase the risk of diabetic ketoacidosis, a serious condition where the body produces high levels of ketones. This can occur even when blood sugar levels aren’t very high. Warning signs include:

• Persistent nausea or vomiting
• Stomach pain
• Excessive thirst
• Unusual fatigue
• Fruity-smelling breath

Gastrointestinal side effects

Mounjaro commonly causes nausea, vomiting, or diarrhoea, particularly when first starting. These side effects can increase the risk of dehydration when combined with SGLT2 inhibitors.

Clinical guidelines recommend stopping SGLT2 inhibitors temporarily during:

• Surgical procedures
• Severe illness
• Extended fasting
• Acute kidney injury

This is often referred to as the ‘sick day rules’ and should be discussed with your healthcare team.

NHS guidance and recommendations

Current UK guidance (NICE NG28) provides recommendations for type 2 diabetes treatment that can include combination therapy for patients who haven’t achieved adequate blood sugar control on single medications.

The pathway typically positions this type of combination as appropriate for consideration in:

1. Patients whose HbA1c remains above target despite metformin and either Mounjaro or an SGLT2 inhibitor
2. People with established cardiovascular disease, heart failure, or chronic kidney disease
3. Patients needing additional blood glucose control or weight management support

Access to Mounjaro (tirzepatide) through NHS pathways may vary by region, as it’s a newer medication. Many UK patients currently access Mounjaro through private prescription.

Most clinical guidelines follow a stepwise approach:

1. Metformin as first-line therapy
2. Second-line options, including SGLT2 inhibitors (particularly for those with heart or kidney concerns)
3. Further options, including GLP-1 receptor agonists like Mounjaro, particularly for patients needing significant weight loss
4. Combination therapies when individual medications don’t achieve targets

When considering combination therapy, your healthcare team will evaluate your individual circumstances, comorbidities, and treatment goals to determine the most appropriate approach.

Practical advice for patients

If you’re taking or considering this combination, these practical strategies can help manage it effectively:

Optimal timing

• Take your SGLT2 inhibitor in the morning to minimise nighttime urination
• Administer Mounjaro on a consistent day each week
• Discuss with your healthcare provider whether to space initial doses when first starting both medications

Hydration strategies

• Ensure adequate daily fluid intake
• Carry water with you consistently
• Consider setting hydration reminders
• Monitor urine colour (pale yellow indicates you’re well hydrated)

Side effect management

• For nausea from Mounjaro: smaller, more frequent meals; ginger tea; avoiding fatty foods
• For genital infections from SGLT2 inhibitors: proper hygiene, cotton underwear, and prompt treatment
• For constipation: increase fibre gradually, stay active, and eat a diet based on whole foods (primarily cooked vegetables)

Blood sugar monitoring

• Check glucose more frequently when first combining these medications
• Be particularly vigilant about monitoring if you also take insulin or sulfonylureas
• Know the symptoms of hypoglycaemia, even though the risk is relatively low with this specific combination

Medical ID and communication

• Carry information about both medications
• Ensure your GP, diabetes team, and any other specialists are aware of this combination
• Consider a medical ID bracelet if you have multiple health conditions

Sick day management

• Contact your healthcare team promptly if you develop vomiting or diarrhoea
• Temporary suspension of SGLT2 inhibitors may be necessary during significant illness
• Continue Mounjaro unless advised otherwise by your healthcare provider

What to expect

While individual responses vary significantly, clinical trials provide some general insights into what patients might experience with this combination:

Initial adjustment period

• Increased urination is common with SGLT2 inhibitors
• Digestive symptoms may occur with Mounjaro, particularly during dose titration
• Focus on hydration and managing initial side effects
• You may notice reduced hunger and thirst

Blood sugar improvements

• Most patients see gradual improvements in blood glucose readings
• Your healthcare team will monitor your HbA1c to assess effectiveness
• The full benefits may take several months to develop

Weight loss

• Both medications can contribute to weight loss
• The pace and amount of weight change vary significantly between individuals
• Regular monitoring helps ensure healthy and appropriate weight changes

Medication adjustments

• Your doctor may need to adjust doses of other medications you take
• Blood pressure medications, in particular, may require modification
• Regular check-ups help ensure optimal treatment

Long-term considerations

• Ongoing kidney function monitoring is important
• Annual diabetes reviews should assess continuing benefit
• Your treatment plan may evolve based on your response and health status

Remember that responses to medication vary considerably based on genetics, adherence, lifestyle factors, and the use of other medications.

Frequently asked questions

Will this combination cause excessive weight loss?

Both medications can contribute to weight loss, but responses vary significantly between individuals.

Your healthcare team will monitor your weight regularly and adjust your treatment as needed.

Weight loss with these medications typically occurs gradually when used appropriately.

Do I need to check my ketones while on this combination?

For most patients, routine ketone testing isn’t necessary. However, your doctor may recommend ketone monitoring if you have specific risk factors.

If you experience persistent nausea, vomiting, or unusual fatigue, checking ketones may be valuable, and you should contact your healthcare provider.

Can I drink alcohol while taking both medications?

Caution is advised with alcohol consumption. Both medications may enhance the dehydration effects of alcohol, and SGLT2 inhibitors specifically can increase ketone production.

Discuss alcohol use with your healthcare provider for personalised guidance.

Will my insurance or the NHS cover both medications?

NHS coverage varies by region and individual circumstances. SGLT2 inhibitors are widely available through NHS prescribing for appropriate patients.

Mounjaro (tirzepatide) may have more restricted NHS access in some areas. Private health insurance coverage also varies, so be sure to check with your provider for specific coverage details.

Should I take both medications if I’m having surgery?

SGLT2 inhibitors should typically be temporarily stopped before planned surgical procedures according to clinical guidelines.

Decisions about Mounjaro use depend on the type of procedure and your medical history.

Always inform your surgical team about both medications well in advance of any procedure.

Take home message

The combination of Mounjaro with SGLT2 inhibitors offers potential benefits for blood sugar control and weight management through complementary mechanisms.

While both medications can cause overlapping side effects, particularly related to dehydration, many patients can manage these successfully with proper hydration and monitoring.

Clinical guidelines recommend considering this combination for patients who do not achieve targets on single therapies, particularly those with cardiovascular risk factors or who require additional glycemic control.

It’s essential to focus on proper hydration, consistent monitoring, and open communication with your healthcare team.

If you’re considering or currently taking this combination, focus on developing sustainable habits related to medication timing, hydration, and managing side effects.

With proper support, this medication pairing may offer improvements in both diabetes control and overall health outcomes.